The National Actinium-225 Survey: Understanding the Future of Actinium-Based Therapies

The landscape of radiopharmaceuticals and targeted alpha therapies is evolving rapidly, with Actinium-225 emerging as one of the most promising radionuclides in precision oncology.

As global research, clinical interest, and investment in theranostics continue to accelerate, we are presented with a significant opportunity – but also an important challenge. To realise the full potential of Actinium-based therapies, the sector must first better understand its current capabilities, future needs, and the barriers that may impact growth, access, and clinical readiness.

To help address this need, Oncothera Advocacy has partnered with the Radiopharma Initiative to launch The National Actinium-225 Survey.

This research initiative aims to gather insights from across the healthcare, research, academic, regulatory, and radiopharmaceutical sectors to better understand the current and future landscape for Actinium-based therapies.

Why Conduct a National Actinium-225 Survey?

The development of targeted alpha therapies is progressing at an unprecedented pace internationally. Clinical programs involving Actinium-225 are expanding across a range of cancers, while governments, healthcare institutions, researchers, and industry stakeholders are increasingly recognising the strategic importance of theranostics and radiopharmaceutical medicine.

However, despite this momentum, there remains limited visibility into several critical areas across the region, including:

• Current clinical and research activity

• Institutional readiness and infrastructure capacity

• Workforce capability and training needs

• Manufacturing and isotope supply considerations

• Clinical trial demand and future pipeline expectations

• Regulatory and operational barriers

• Cross-sector collaboration opportunities

Without a clearer understanding of these factors, it becomes more difficult to effectively plan for future growth, advocate for investment, support clinical adoption, or identify where resources and collaboration are needed most.

The National Actinium-225 Survey has been designed to help establish that foundation.

Building a More Informed Future

The insights gathered through the survey will contribute to a broader understanding of how the sector is preparing for the next generation of radiopharmaceutical therapies.

Importantly, the survey is not limited to a single stakeholder group. The future of theranostics relies on collaboration across a complex ecosystem that includes clinicians, hospitals, universities, regulators, CROs, manufacturers, researchers, and industry partners.

By bringing together perspectives from across these sectors, the initiative aims to identify:

• Emerging trends and priorities

• Areas of unmet need

• Infrastructure and capability gaps

• Opportunities for strategic partnerships

• Future education and workforce requirements

• Key considerations for long-term sector development

The findings may also help inform future advocacy initiatives, policy discussions, research priorities, and broader strategic planning efforts within the theranostics community.

A Critical Time for Collaboration

The theranostics sector has demonstrated strong capabilities in nuclear medicine and radiopharmaceutical innovation. However, as international competition and demand for radioisotopes continue to increase, strategic planning, coordination, and cross-sector collaboration will become increasingly important.​

Understanding where the market currently stands – and where it is heading – is essential to ensuring the sector remains well positioned to support future clinical, research, and commercial advancements.​

The National Actinium-225 Survey represents an important step toward building that understanding..

We Encourage Broad Participation

Oncothera Advocacy and the Radiopharma Initiative encourage participation from stakeholders across:

• Nuclear medicine

• Medical oncology

• Radiation oncology

• Clinical research

• Universities and academic institutions

• CROs and trial networks

• Public and private healthcare institutions

• Radiopharmaceutical companies

• Regulatory and policy organisations

Whether your organisation is already actively involved in Actinium-based therapies, exploring future opportunities, or preparing for future clinical adoption, your perspective is valuable.

The broader the participation, the stronger and more meaningful the insights will become.

Together, we can help build a clearer understanding of the future needs, opportunities, and priorities shaping Actinium-based therapies across the region.

Participate in The National Actinium-225 Survey, here: https://bit.ly/4tiHALm